Sarepta Therapeutics Inc. has licensed rights to two gene therapy research programs underway at the Nationwide Children’s Hospital, Columbus, Ohio, adding new projects to its growing Duchenne muscular dystrophy pipeline to complement its recently launched lead DMD product Exondys 51 (eteplirsen).
Marketing a range of therapies for a specific disease or condition is a well-established strategy for pharmaceutical companies, particularly in a disease like DMD that is mediated by a number of different genetic mutations